Foley Mark J

CIK 00015291964 companiesALISO VIEJO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001529196

Recent Transactions

50 trades

Award
GLAUKOS Corp$GKOS
Common Stock
2026-01-02+1,168→ 58,389 total
Award
GLAUKOS Corp$GKOS
Stock Option (Right to Buy)
2025-05-29+3,149→ 3,149 total
Award
GLAUKOS Corp$GKOS
Common Stock
2025-05-29+2,108→ 57,221 total
Exercise/Conversion
GLAUKOS Corp$GKOS
Common Stock
2025-02-26$24.69/sh+15,000→ 74,936 total
Exercise/Conversion
GLAUKOS Corp$GKOS
Stock Option (Right to Buy)
2025-02-26−15,000→ 0 total
Exercise/Conversion
GLAUKOS Corp$GKOS
Stock Option (Right to Buy)
2025-02-26−25,000→ 0 total
Sale
GLAUKOS Corp$GKOS
Common Stock
2025-02-26$120.72/sh−20,687→ 54,249 total
Exercise/Conversion
GLAUKOS Corp$GKOS
Common Stock
2025-02-26$32.00/sh+25,000→ 59,936 total
Award
Revance Therapeutics, Inc.
Common Stock
2025-02-06+84,686→ 84,686 total
Disposition to Issuer
Revance Therapeutics, Inc.
Common Stock
2025-02-06−84,686→ 0 total
Disposition to Issuer
Revance Therapeutics, Inc.
Common Stock
2025-02-06−27,933→ 0 total
Disposition from Tender
Revance Therapeutics, Inc.
Common Stock
2025-02-04$3.65/sh−996,935→ 27,933 total
Disposition from Tender
Revance Therapeutics, Inc.
Common Stock
2025-02-04$3.65/sh−110,913→ 0 total
Award
Revance Therapeutics, Inc.
Common Stock
2025-02-03+27,933→ 1,024,868 total
Award
GLAUKOS Corp$GKOS
Common Stock
2025-01-02+864→ 35,800 total
Award
Revance Therapeutics, Inc.
Common Stock
2024-12-31$2.18/sh+1,000→ 996,935 total
Award
Revance Therapeutics, Inc.
Common Stock
2024-06-30$2.18/sh+1,000→ 995,935 total
Award
GLAUKOS Corp$GKOS
Common Stock
2024-05-30+1,716→ 34,936 total
Award
GLAUKOS Corp$GKOS
Stock Option (Right to Buy)
2024-05-30+1,246→ 1,246 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2024-03-15$5.30/sh−3,305→ 1,012,163 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2024-03-15$5.30/sh−17,228→ 994,935 total
Purchase
Revance Therapeutics, Inc.
Common Stock
2024-03-06$6.98/sh+30,000→ 1,015,468 total
Award
Revance Therapeutics, Inc.
Common Stock
2024-02-29+70,750→ 985,468 total
Exercise/Conversion
GLAUKOS Corp$GKOS
Stock Option (Right to Buy)
2024-02-23−10,000→ 0 total
Sale
GLAUKOS Corp$GKOS
Common Stock
2024-02-23$92.87/sh−4,560→ 33,220 total
Exercise/Conversion
GLAUKOS Corp$GKOS
Common Stock
2024-02-23$7.28/sh+10,000→ 37,780 total
Award
Revance Therapeutics, Inc.
Performance Stock Units
2024-01-31+1,070,001→ 1,070,001 total
Award
Revance Therapeutics, Inc.
Common Stock
2023-12-31$7.47/sh+264→ 914,718 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2023-08-11$18.91/sh−48,064→ 914,454 total
Award
Revance Therapeutics, Inc.
Common Stock
2023-08-11+122,143→ 962,518 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-08-03$22.57/sh−26,279→ 840,375 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-07-03$24.94/sh−26,279→ 866,654 total
Award
Revance Therapeutics, Inc.
Common Stock
2023-06-30$15.61/sh+1,000→ 892,933 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-06-09$30.72/sh−31,279→ 891,933 total
Award
GLAUKOS Corp$GKOS
Common Stock
2023-06-01+3,230→ 27,780 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-05-15$34.55/sh−70,447→ 923,212 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2023-03-15$30.65/sh−5,341→ 818,010 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-03-09$31.59/sh−70,390→ 823,351 total
Award
GLAUKOS Corp$GKOS
Common Stock
2023-01-03+2,948→ 24,550 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-12-31$12.18/sh+605→ 718,092 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2022-10-13$26.97/sh−49,274→ 717,487 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-09-22+175,649→ 893,741 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-06-30$11.75/sh+1,000→ 766,761 total
Award
GLAUKOS Corp$GKOS
Common Stock
2022-06-02+4,364→ 21,602 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2022-03-15$15.79/sh−3,304→ 765,761 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-02-02+175,649→ 993,659 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2022-02-02+143,354→ 143,354 total
Award
GLAUKOS Corp$GKOS
Common Stock
2022-01-03+2,486→ 17,238 total
Purchase
Revance Therapeutics, Inc.
Common Stock
2021-11-29$12.90/sh+40,000→ 110,913 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2021-10-13$23.08/sh−42,096→ 769,065 total

Companies

Recent Filings

Address

C/O GLAUKOS CORPORATION ONE GLAUKOS WAY

ALISO VIEJO, CA, 92656

View on SEC.gov